Search Results

You are looking at 61 - 70 of 1,243 items for :

  • Refine by Access: All x
Clear All
Full access

Vishruth K. Reddy, Varsha Jain, Sriram Venigalla, William P. Levin, Robert J. Wilson II, Kristy L. Weber, Anusha Kalbasi, Ronnie A. Sebro, and Jacob E. Shabason

involving surgery, radiation oncology, medical oncology, radiology, and pathology. 2 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for STS recommend the addition of neoadjuvant or adjuvant radiation therapy (RT) to surgery for patients

Full access

Aparna Balakrishnan, Kirsten Bell Burdett, Masha Kocherginsky, and Neil Jordan

status, education status, and income. Black and AI/AN patients had higher odds of refusing recommended surgery (OR=1.95; 95% CI: 1.57-2.42; p<0.001, and OR=2.13; 95% CI: 1.11-4.10; p=0.024, respectively). Hispanic patients had slightly higher odds of

Full access

Jordan E. Rullo and Sandhya Pruthi

preoperatively. 2 For women undergoing risk-reducing surgeries for elevated breast or ovarian cancer risk or hereditary predisposition, the impact on sexual health is one of the most influential factors when deciding to undergo these surgeries. 3 Among BRCA

Full access

Andrea Cercek, Karyn A. Goodman, Carla Hajj, Emily Weisberger, Neil H. Segal, Diane L. Reidy-Lagunes, Zsofia K. Stadler, Abraham J. Wu, Martin R. Weiser, Philip B. Paty, Jose G. Guillem, Garrett M. Nash, Larissa K. Temple, Julio Garcia-Aguilar, and Leonard B. Saltz

those of local recurrence. 1 , 2 The current standard management for stage II (T3/T4N0) and stage III (TanyN1/N2) rectal cancer is neoadjuvant chemoradiotherapy, followed by surgery, with 4 months of adjuvant systemic chemotherapy given at the end. 1

Full access

Sandra O. Gollnick

treated with PDT or surgically removed. Both before and after PDT, “we saw an increased T-cell response against that Hip1 antigen that we did not see following surgery,” Dr. Gollnick reported. This systemic antitumor immune response was inversely

Full access

Kan Wu, Xu Liu, Zhihong Liu, Yiping Lu, Xianding Wang, and Xiang Li

Background Adrenocortical carcinoma (ACC) is a rare but highly aggressive tumor with an estimated incidence of 0.7 to 2.0 per 1,000,000 adult individuals annually. 1 Radical surgery is still the mainstay treatment of patients with

Full access

Angela W Zhang, Camille M Powers, Kathryn E Gallaway, and Alexandra K Callan

Background : Leg length discrepancy (LLD) is a potential long-term complication in skeletally immature patients with lower extremity bone tumors undergoing limb salvage surgery. Surgical reconstruction violates the epiphyseal plates around the

Full access

Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum-Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Lee-may Chen, Mihaela Cristea, Maria DeRosa, Eric L. Eisenhauer, David M. Gershenson, Heidi J. Gray, Rachel Grisham, Ardeshir Hakam, Angela Jain, Amer Karam, Gottfried E. Konecny, Charles A. Leath III, Joyce Liu, Haider Mahdi, Lainie Martin, Daniela Matei, Michael McHale, Karen McLean, David S. Miller, David M. O’Malley, Sanja Percac-Lima, Elena Ratner, Steven W. Remmenga, Roberto Vargas, Theresa L. Werner, Emese Zsiros, Jennifer L. Burns, and Anita M. Engh

Overview Primary treatment of presumed ovarian, fallopian tube, or primary peritoneal cancer usually consists of appropriate surgical staging and debulking surgery, followed in most (but not all) patients by systemic chemotherapy (OV-1, OV-4, above

Full access

Joyce Valerie Veld, Femke Julie Amelung, Wernard Aat Antoine Borstlap, Emo Eise van Halsema, Esther Catharina Josephina Consten, Peter Derk Siersema, Frank ter Borg, Edwin Silvester van der Zaag, Paul Fockens, Willem Adrianus Bemelman, Jeanin Elise van Hooft, Pieter Job Tanis, and for the Dutch Snapshot Research Group

postoperative morbidity and mortality. 1 Initial decompression of a distended colon as a bridge to surgery (BTS) is likely to change the risk profile of the patient, but it requires an additional intervention with its own disadvantages. The construction of a

Full access

Judy George, Joseph Tkacz, M. Christopher Roebuck, Fredy Reyes, Yull E. Arriaga, Gretchen P. Jackson, and Irene Dankwa-Mullan

Background: Breast Conserving Surgery (BCS) is now considered an acceptable alternative to mastectomy for patients with early stage invasive breast cancer (ESBCa). Limited research examining factors influencing choice of BCS reveal important